T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

(MedPage Today) -- CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab...